Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇨🇦CA · Medicine#1825K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
2.5K to 15K🎙 ~2x weekly·18 episodes·Last published 2d ago - Monthly Reach
Unique listeners across all episodes (30 days)
5K to 30K🇨🇦100% - Active Followers
Loyal subscribers who consistently listen
2K to 12K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Abema and Ribo - Adjuvant High Risk EBC with Dr. Aalok Kumar
May 13, 2026
Unknown duration
Targeted therapy in Cholangiocarcinoma - Part 2 - Ivosidenib
Apr 23, 2026
Unknown duration
Targeted therapy in Cholangiocarcinoma - Part 1 - Pemigatinib
Apr 2, 2026
Unknown duration
You Are What You Eat - Diet and Cancer with Dr. Urvi Shah
Mar 18, 2026
Unknown duration
Targeting HER2 Alterations in NSCLC with Dr. Barbara Melosky
Feb 6, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 5/13/26 |  Abema and Ribo - Adjuvant High Risk EBC with Dr. Aalok Kumar | In this episode, Dr. Aalok Kumar takes us through the practical aspects of choosing between the available adjuvant intensification options in "High Risk" HR+, HER2 - Early Breast Cancer. This is timely given there is public funding for Abemaciclib and PSP support for Ribociclib. | — | ||||||
| 4/23/26 |  Targeted therapy in Cholangiocarcinoma - Part 2 - Ivosidenib | In this episode, Dr. Arndt Vogel takes us through targeted therapy in Biliary Tract Cancers. As we now have access to Pemigatinib (PART 1) to target FGFR2 fusions and Ivosidenib (PART 2) for IDH1 mutated cholangiocarcinoma, I thought it important to discuss how to incorporate these into practice. | — | ||||||
| 4/2/26 |  Targeted therapy in Cholangiocarcinoma - Part 1 - Pemigatinib | In this episode, Dr. Arndt Vogel takes us through targeted therapy in Biliary Tract Cancers. As we now have access to Pemigatinib to target FGFR2 fusions and Ivosidenib for IDH1 mutated cholangiocarcinoma, I thought it important to discuss how to incorporate these into practice. | — | ||||||
| 3/18/26 |  You Are What You Eat - Diet and Cancer with Dr. Urvi Shah | In this episode, Dr. Urvi Shah takes us through how to optimize diet in cancer treatment and prevention. | — | ||||||
| 2/6/26 |  Targeting HER2 Alterations in NSCLC with Dr. Barbara Melosky | In this episode, Dr. Barb Melosky takes us through practical aspects of using HER2 targeted agents in HER2 altered advanced NSCLC. This is particularly timely given we now have access through company sponsored SAP programs for both Zongertinib and Sevabertinib. | — | ||||||
| 1/19/26 |  Choosing in Advanced NSCLC - Without AGA, and EGFR+ with Dr. Natasha Leighl | In this episode, Dr. Natasha Leighl takes us through practical aspects of choosing treatments in advanced NSCLC without AGA and then in EGFR + NSCLC. We discuss treatments that are routinely available in clinic. | — | ||||||
| 12/23/25 |  Sequencing in Advanced Colorectal Cancer - with Dr. Scott Berry | In this episode, Dr. Scott Berry takes us through practical discussions on sequencing the increasing available treatment options for Advanced Colorectal cancer. | — | ||||||
| 11/24/25 |  BREAKWATER: Charting New Waters in Advanced BRAFmt CRC with Dr. Rachel Goodwin | As we now access Encorafenib + Cetuximab + Folfox via a Pfizer sponsored PSP for the he first line treatment Braf V600e mutated, RAS wt, dMMR/MSS metastatic Colorectal cancer, Dr. Rachel Goodwin takes us through the regimen, its practical use and efficacy and toxicity management. | — | ||||||
| 10/7/25 |  Inavolisib in Endocrine Resistant PIK3CA Mutated HR+, HER2- Breast Cancer with Dr. Kasia Jerzak | As we now have access to Inavolisib via a ROCHE sponsored PSP for the first line treatment of endocrine resistant HR+ HER2- PIK3CA altered breast cancer progressing on or after adjuvant endocrine therapy, Dr. Kasia Jerzak takes us through the regimen, its practical use and efficacy and toxicity management. | — | ||||||
| 9/16/25 |  TDXD a new DESTINY for HER2+ Gastro/GEJ adeno in 2nd line with Dr. Brezden-Masley | As we now have funded 2nd line access to TDXD (ENHERTU) in the treatment of HER2 + Gastric and GEJ cancer after Trastuzumab containing regimens, Dr. Christine Brezden-Masley takes us through the regimen, its use and efficacy and toxicity management | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 9/11/25 |  Check or Checkmate Ipi/Nivo in HCC with Dr. Hatim Karachiwala | In this episode of MedOncNow, Dr. Hatim Karachiwala discusses where IPI/NIVO is positioned in the first-line treatment options of advanced HCC. We discuss the regimen's efficacy with a focus on toxicity management. This is particularly timely as BMS has a compassionate access program for Ipilimumab and Nivolumab for advanced HCC. | — | ||||||
| 8/21/25 |  IPI/NIVO for mCRC with Dr. Sharlene Gill | In this episode of MedOncNow, Dr. Sharlene Gill takes us through the evolving changes in the treatment of dMMR/MSI-H mCRC. Given that BMS has a company-sponsored PSP program, I felt it timely to discuss how Ipilimumab and Nivolumab fits into our treatment strategy. | — | ||||||
| 8/11/25 |  The CHALLENGE to Move and Survive: Exercise After Adjuvant Colon Cancer Treatment with Dr. Christopher Booth | In this episode of MedOncNow, Dr. Christopher Booth discusses how 3 years of a structured exercise program after adjuvant chemotherapy for resected colon cancer can improve survival. This is an affordable, accessible and evidence-based strategy that can be incorporated into practice tomorrow. | — | ||||||
| 6/2/25 |  Amivantamab + Lazertinib in 1st line Advanced EGFR + NSCLC - Mariposa | In this episode of MedOncNow, Dr. Kevin Jao discusses Amivantamab + Lazertinib in the first-line treatment of EGFR-mutated NSCLC and how it fits into the treatment landscape. This is timely, as Johnson & Johnson has a time-limited access program to Ami-Laz for EGFR-mutated NSCLC, as per the Mariposa Regimen. More information in episodes 2 and 3. Proudly partnering with Oncology Education for the 2025 season. MedOncNow has been made possible by the generous unrestricted support of BMS, Eisai, Johnson and Jonhson, Merck, Pfizer and Roche Canada. | — | ||||||
| 5/16/25 |  Claudin 18.2 - a SPOTLIGHT on Zolbetuximab - Part 2 of 2 | In this episode of MedOncNow, Dr. Christine Brezden-Masley explores the clinical impact of Zolbetuximab in gastric and GEJ cancers, covering patient selection, treatment integration, and implications for systemic therapy delivery. This is timely as ASTELLAS is funding both testing for Claudin 18.2 and access to Zolbetuximab for Gastric and GEJ cancers across Canada. 🎧 Catch up on Part 1 for insights into Claudin 18.2 testing and its role in guiding therapy decisions. | — | ||||||
| 5/6/25 |  Claudin 18.2 - a GLOW-ing biomarker in Gastric Cancer - Part 1 of 2 | In this episode of MedOncNow, Dr. Brandon Sheffield explores the role of Claudin 18.2 as a biomarker in gastroesophageal junction (GEJ) and gastric cancers. He discusses key considerations for testing and the evolving implications for biomarker-driven treatment in gastric cancer. This conversation is especially timely as ASTELLAS is currently funding Claudin 18.2 testing as part of the Gastric Cancer Biomarker Workflow initiative. Access to Zolbetuximab from ASTELLAS will follow in May 2025. | — | ||||||
| 3/27/25 |  Take 2 Aspirin and call me in the morning - Adjuvant therapy for Colorectal Cancer | Dr. Brandon Meyers joins Dr. Kassam to discuss the use of Adjuvant Aspirin in the management of curatively resected Colorectal Cancer in patients harbouring alterations in the PI3 Kinase pathway. This is a potentially practice-changing implementation of an affordable and tolerable drug that is easily accessible to patients. | — | ||||||
| 3/3/25 |  Resectable NSCLC: How to Choose the Right Treatment | In episode 3 of MedOncNow, Dr. Parneet Cheema joins Dr. Kassam to discuss how to implement the multiple options available for treating resectable NSCLC. She will help us choose between CheckMate 816 and KEYNOTE-671 while also discussing CheckMate-77T, AEGEAN and IMpower010. | — | ||||||
| 2/18/25 |  2L Treatment of EGFR-Positive NSCLC | Practically Speaking: Mariposa-2. In this episode of MedOncNow, Dr. Barb Melosky joins Dr. Kassam to discuss the use of Amivantimab + Carboplatin + Pemetrexed in the second-line treatment of EGFR-positive non small cell lung cancer (NSCLC) progressing after Osimertinib. A timely discussion, given that Johnson & Johnson now has a compassionate access program for this regimen. | — | ||||||
| 1/31/25 |  Belzutifan - A Spark of Light for Clear Cell Renal Cell Carcinoma | Dr. Kassam is joined by Dr. Aly-Khan Lalani to discuss the use of Belzutifan in the management of previously treated clear cell renal cell carcinoma. With Belzutifan now available in clinic, listen today for important guidance. | — | ||||||
Showing 20 of 20
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.